Premium
Angiogenesis‐related growth factors and cytokines in the serum of patients with B non‐Hodgkin lymphoma; relation to clinical features and response to treatment
Author(s) -
PASSAM F. H.,
SFIRIDAKI A.,
PAPPA C.,
KYRIAKOU D.,
PETRELI E.,
ROUSSOU P. A.,
ALEXANDRAKIS M. G.
Publication year - 2008
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/j.1365-2257.2006.00890.x
Subject(s) - angiogenesis , angiogenin , medicine , lymphoma , stage (stratigraphy) , gastroenterology , vascular endothelial growth factor , interleukin , cytokine , oncology , immunology , vegf receptors , biology , paleontology
Summary Increased angiogenesis has been shown to be a feature of non‐Hodgkin lymphomas (NHL). In the current study, the pretreatment levels of circulating molecules related to angiogenesis were determined in 49 B‐cell NHL patients and correlated with histological grade, disease stage and prognostic score. In 25 patients, the same molecules were defined after standard treatment. Vascular endothelial growth factor (VEGF), angiogenin, interleukin‐2 (IL‐2), IL‐6, IL‐8 and IL‐16 were measured. Increased levels of VEGF, IL‐6 and IL‐8 were found in the whole group of untreated patients in comparison with normal controls ( P < 0.05), whereas, IL‐2 was higher in the subgroup of indolent NHL. Overall, there was no significant decrease in the levels of these molecules after treatment. However, by stratification into group of responders vs. non‐responders pretreatment IL‐8 was significantly increased whereas IL‐16 was decreased in the subgroup of complete responders. According to the REAL classification IL‐2 was higher in the low risk compared with intermediate plus high‐risk group. There was no association with disease stage or the International Prognostic Score. Both indolent and aggressive B cell lymphomas have increased production of angiogenic mediators and cytokines with IL‐8 and IL‐16 potentially reflecting the response to treatment.